This paper is only available as a PDF. To read, Please Download here.
Abstract
In 1985, plasma cholesterol, triglyceride, high-density lipoprotein cholesterol, and
plasma apoprotein (apo) B levels were measured in 2,103 men (aged 45 to 76 years)
without ischemic heart disease from the Que´bec city suburbs. Occurrence of a first
ischemic event (i.e., angina pectoris, acute myocardial infarction, or coronary-related
death) was recorded in 114 men between 1985 and 1990. Men with and without ischemic
heart disease were classified as normal or in various dyslipidemic groups according
to an established algorithm. Of the 1,989 men who remained free of ischemic events,
50% had a normal lipid profile compared with 32% in men with ischemic heart disease.
Although the prevalence of type IIb and IV dyslipidemias was similar in men with and
without ischemic heart disease, type lia (16% vs 10%), hyperapo B-hypertriglyceridemia
(12% vs 6%), hyperapo B-normotriglyceridemia (11% vs 7%), and hypoalphalipoproteinemia
(18% vs 13%) were more prevalent in men with than without ischemic heart disease.
Adjusted odds ratios (ORs) were not increased in type IIb and IV phenotypes, whereas
men with type IIa (OR 2.8), with the 2 hyperapo B phenotypes (hyperapo B-normotriglyceridemia,
OR 2.7; hyperapo B-hypertriglyceridemia, OR 3.1) or with isolated hypoalphalipoproteinemia
(OR 2.2), were at higher risk. The results of this prospective study confirm the importance
of both elevated plasma cholesterol and decreased high-density lipoprotein cholesterol
levels as risk factors for ischemic heart disease. They also emphasize the high prevalence
of an elevated apo B dyslipidemic state in ischemic heart disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Epidemiology of coronary heart disease: The Framingham Study.Am J Med. 1984; 76: 4-12
- Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).JAMA. 1986; 256: 2823-2828
- Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.Lancet. 1986; 2: 933-936
- Prevalence of risk factors in men with premature coronary heart disease.Am J Cardiol. 1991; 67: 1185-1189
- Plasma high density lipoprotein concentration and development of ischaemic heart disease.Lancet. 1976; 1: 16-18
- Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human low density lipoproteins).in: 6th ed. Proc Natl Acad Sci USA. 77. 1980: 604-608
- Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.Ann Intern Med. 1982; 97: 833-839
- Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease.Am J Cardiol. 1993; 71: 631-639
- First coronary heart disease event rate in relation to major risk factors. Quebec Cardiovasular Study.Can J Cardiol. 1990; 6: 274-280
- Chylomicronemia syndrome.Adv Intern Med. 1992; 37: 249-273
- Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study.JAMA. 1986; 256: 2835-2838
- International diagnostic criteria for acute myocardial infarction and acute stroke.Am Heart J. 1984; 108: 150-158
- Automated simultaneous cholesterol and triglyceride determination on the autoanalyzer II instrument.Technicon Instrument Corporation, Tarrytown, NY1972
- Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoproteins.Clin Chem. 1978; 24: 853-856
- Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge.Clin Chem. 1972; 18: 499-502
- Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.Ann Biochem. 1960; 5: 609-610
- Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.Metabolism. 1987; 36: 244-250
- Lipid research clinics program reference values for hyperlipidemia and hypolipidemia.JAMA. 1983; 250: 1869-1872
- Canadian Consensus Conference on Cholesterol: final report.in: Canadian consensus conference on the prevention of heart and vascular disease by altering serum cholesterol and lipoprotein risk factors. 6th ed. Can Med Assoc J. 139. 1988: 1-8 (suppl II)
- Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.J Am Coll Cardiol. 1992; 19: 792-802
- Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.Circulation. 1990; 82: 495-506
- Plasma triglyceride and coronary heart disease.Arterioscler Thromb. 1991; 11: 2-14
- Epidemiology as a guide to clinical decision: the association between triglyceride and coronary heart disease.N Engl J Med. 1980; 302: 1383-1389
- Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease.Am J Cardiol. 1990; 65: 1-5
- Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with desirable total cholesterol levels.Am J Cardiol. 1991; 68: 187-192
- Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol.Arch Intern Med. 1992; 152: 2412-2416
Article Info
Publication History
Accepted:
February 6,
1995
Received in revised form:
February 2,
1995
Received:
October 26,
1994
Footnotes
This study was supported in part by the National Health Research Development and Welfare Canada (Ottawa), the Heart and Stroke Foundation of Canada (Ottawa), and by a financial contribution from Fournier Pharma/ Jouveinal, Montre´al, Canada.
Identification
Copyright
© 1995 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.
